{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.7","upperLimit":"59.4","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks","dispersionType":"95% Confidence Interval","groups":[{"description":"During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.\n\nCDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.","id":"OG000","title":"CDX-3379 and Cetuximab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every 8 weeks, starting with first dose until disease progression, assessed up to approximately 2 years","title":"Clinical Benefit Response (CBR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}